MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ
20.25
-1.32
-6.12%
After Hours: 20.63 +0.38 +1.88% 19:41 05/11 EDT
OPEN
21.81
PREV CLOSE
21.57
HIGH
22.02
LOW
19.80
VOLUME
2.88M
TURNOVER
--
52 WEEK HIGH
24.27
52 WEEK LOW
3.390
MARKET CAP
1.06B
P/E (TTM)
-3.4686
1D
5D
1M
3M
1Y
5Y
1D
Avalo Therapeutics Price Target Raised to $60.00/Share From $48.00 by Piper Sandler
Dow Jones · 12h ago
Avalo Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 12h ago
Piper Sandler Maintains Overweight on Avalo Therapeutics, Raises Price Target to $60
Benzinga · 12h ago
Weekly Report: what happened at AVTX last week (0504-0508)?
Weekly Report · 14h ago
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Reuters · 16h ago
AVALO THERAPEUTICS INC <AVTX.O>: PIPER SANDLER RAISES TARGET PRICE TO $60 FROM $48
Reuters · 20h ago
Avalo CFO Christopher Sullivan disposes of common shares worth $1.03 million
PUBT · 4d ago
Avalo CMO Mittie Doyle disposes 108,234 shares worth $2.28 million
PUBT · 4d ago
More
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Webull offers Avalo Therapeutics Inc stock information, including NASDAQ: AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.